AxoGen (AXGN) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXGN shares.
View AXGN analyst ratings or view top-rated stocks.

4 equities research analysts have issued 12 month target prices for AxoGen's shares. Their AXGN share price forecasts range from $15.00 to $20.00. On average, they predict the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 240.2% from the stock's current price.
View analysts price targets for AXGN or view top-rated stocks among Wall Street analysts.

AxoGen's stock was trading at $9.98 at the beginning of 2023. Since then, AXGN shares have decreased by 51.4% and is now trading at $4.85.
View the best growth stocks for 2023 here.

AxoGen saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,410,000 shares, an increase of 21.6% from the August 15th total of 1,160,000 shares. Based on an average trading volume of 275,400 shares, the days-to-cover ratio is currently 5.1 days. Approximately 3.6% of the company's shares are sold short.
View AxoGen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our AXGN earnings forecast.

AxoGen, Inc. (NASDAQ:AXGN) released its quarterly earnings results on Monday, August, 7th. The medical equipment provider reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.07. The medical equipment provider earned $38.16 million during the quarter, compared to analyst estimates of $39.40 million. AxoGen had a negative trailing twelve-month return on equity of 19.48% and a negative net margin of 15.86%.

iShares Neuroscience and Healthcare ETF holds 5,003 shares of AXGN stock, representing 0.66% of its portfolio.

AxoGen updated its FY 2023 earnings guidance on Monday, August, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $154.00 million-$159.00 million, compared to the consensus revenue estimate of $157.43 million.

19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

AxoGen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (9.12%), BlackRock Inc. (7.66%), William Blair Investment Management LLC (3.75%), Perceptive Advisors LLC (3.41%), Silvercrest Asset Management Group LLC (2.15%) and State Street Corp (2.14%). Insiders that own company stock include Amy Mcbride Wendell, Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Guido J Neels, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan, Peter J Mariani and William P Mr Burke.
View institutional ownership trends.

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXGN stock can currently be purchased for approximately $4.85.

AxoGen (NASDAQ:AXGN) has a market capitalization of $208.45 million and generates $138.58 million in revenue each year. The medical equipment provider earns $-28,950,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

The company employs 394 workers across the globe.

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The official website for the company is www.axogeninc.com. The medical equipment provider can be reached via phone at (386) 462-6800, via email at investorrelations@axogeninc.com, or via fax at 386-462-6801.